| Heading: |
Semaglutide: Artificial Intelligence |
| Question ID: |
1796541 |
| UIN: |
HL6784 |
| House: |
Lords |
| Date tabled: |
2025-04-23 |
| Asking Member ID: |
2593 |
| Asking Member display name: |
Lord Freyberg
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Lord Freyberg
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what assessment they have made of the (1) benefits and (2) risks of using wearable technology and AI-driven monitoring systems to track vital signs in patients who are prescribed semaglutide; and whether those systems could |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-04-30 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence has published early value assessment guidance on digital technologies for delivering multidisciplinary weight management services. This includes recommendations on which technologies can be used in the... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |